Latest Articlesddd
Congratulations. The FDA approved Exelixis’ (EXEL) drug Cabometyx™ (cabozantinib) tablets for advanced renal cell carcinoma …
The AACR 2016 meeting presentations differed substantially from previous meetings. The 2016 meeting has brought near …
Illumina Showing 6% revenue increase over the same quarter last year, Q1 2016, was not enough as Illumina …
Meaningful Presentations at the Annual Meeting of the American Association for Cancer Research (AACR) NEKTAR THERAPEUTICS …
In the biotech sector, daily stories (news) are not just announced, but mostly edited in ways …
Pursuing its goal in treating hepatitis, Gilead Sciences (GILD) is at the finish line of clinical trials on …
Juno Therapeutics (JUNO) is due to receive a fee payment of $50 million from Celgene. The reason …
Regeneron and Intellia to Discover and Develop CRISPR/Cas Therapeutics Moving forward is Regeneron Pharmaceuticals’ (REGN) strategy based on strong …
Dealing With Bacterial Resistance To Antibiotics In the NEWS THERAVANCE BIOPHARMA At the 26th European Congress …
Another day, another badly needed treatment for a dangerous disease is on its way to be …
Years ago, a friend who is a highly regarded Immunologist lectured us during one of our …
Pfizer (PF) terminated its acquisition agreement with Allergan Plc (AGN) The new set of rules released by …
PFIZER Pfizer (PF) announced that its oral drug tofacitinib in doses of 5 mg and 10 mg …
Prohost Letter #394 Part 2 PART 2 - Part 1 of the Prohost letter issue #394 posted …
Many in Wall Street have been anxious, sitting on fire while waiting to learn, which biotech …
Prohost Letter #394 Part 1 Gilead - Some people sold Gilead’s (GILD) stock on Wednesday, March 23 …
Incyte (INCY) and Eli Lilly (LLY): The New England Journal of Medicine published detailed results of RA-BEACON — a pivotal …
The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) voted 12 to 2 …
Alder Reports Phase 2b Trial of ALD403 Meets Primary and Secondary Endpoints Demonstrating Migraine Prevention in …
It is an ingenuous decision made by investors who rushed to consider betrixaban Phase 3 APEX study a …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
